pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Effects of pharmacological treatments on body composition, hormone & glucose, and states of hyperphagic behavior
| Study name | Body composition | Hormone & glucose | States of hyperphagic behavior |
|---|---|---|---|
| GH | |||
| Sode-Carlsen et al. (2010) 42) | BMI (kg/m2) unchanged LBM (kg) ↑ FM (kg) ↓ |
IGF-1 (ng/mL) ↑ Fasting glucose (mmol/L) unchanged Fasting insulin (pmol/L) unchanged |
- |
| Festen et al. (2007) 41) | BMI (kg/m2) ↓ Height SDS ↑ |
Glucose (mmol/L) ↓ Insulin (mU/L) ↑ Adiponectin (mg/L) ↑ |
- |
| Bakker et al. (2015) 35) | LBM (kg) ↑ FM (kg) ↑ Body fat (%) ↓ Height (SDS) ↑ |
Fasting glucose ↑ Fasting insulin ↑ Fasting adiponectin (mg/L) ↑ |
- |
| Kuppens et al. (2016 a) 40) | BMI (kg/m2) ↑ LBM (kg) ↑ FM (kg), FM (%) ↑ |
Glucose (mmol/L) ↓ Insulin (pmol/L) ↓ |
- |
| Myers et al. (2000) 30) | BMI (kg/m2) ↓ LBM (kg) ↑ Body fat (%) ↓ |
IGF-1 (ng/mL) ↑ Fasting insulin (mIU/L) ↑ |
- |
| Haqq et al. (2003) 32) | BMI (kg/m2) ↑ LBM (kg) ↑ FM (kg) ↓ Body fat (%) ↓ Height (SDS) ↑ |
- | - |
| Carrel et al. (1999) 18) | BMI (kg/m2) ↓ LBM (kg) ↑ Body fat (%) ↓ Height (SDS) ↑ |
IGF-1 (ng/mL) ↑ IGFBP-3 (mg/L) ↑ Fasting insulin (mIU/L) ↑ |
- |
| Hoybye et al. (2004) 29) | - | Adiponectin (mg/L) ↑ | - |
| Hauffa et al. (1997) 34) | - | IGF-1 ↑ IGFBP-3 ↑ |
- |
| Festen et al. (2008) 33) | BMI (kg/m2) ↓ Height (SDS) ↑ |
IGF-1 (ng/mL) ↑ IGFBP-3 (ng/mL) ↑ |
- |
| Carrel et al. (2004) 38) | LBM (kg) ↑ Body fat (%) ↓ Height (SDS) ↑ |
IGF-1 (ng/mL) ↓ Fasting insulin (mIU/L) ↑ |
- |
| Lindgren et al. (1998) 37) | Body fat (%) ↓ Height (SDS) ↑ |
IGF-1 (SDS) ↑ Fasting insulin (mIU/L) ↑ |
- |
| Hoybye et al. (2003 a) 39) | BMI (kg/m2) ↑ LBM (kg) ↑ Body fat (%) ↓ |
IGF-1 (ng/mL) ↑ Glucose (mmol/L) ↓ Insulin (pmol/L) ↑ |
- |
| Lindgren et al. (1999) 36) | Body fat (%) ↓ Height (SDS) ↑ |
Insulin (mU/L) ↑ | - |
| De Lind van Wijngaarden et al. (2010) 43) | Height (SDS) ↑ | Glucose (mmol/L) ↑ Insulin (mU/L) ↑ |
- |
| Hoybye et al. (2003 b) 31) | - | IGF-1 (ng/mL) ↑ IGFBP-3 (ng/mL) ↑ |
- |
| Non-GH | |||
| Anticonvulsant | |||
| Consoli et al. (2019) 20) | BMI (kg/m2) ↓ | - | ↓ |
| Cannabinoid receptor CB1 inverse agonist | |||
| Motaghedi et al. (2011) 24) | BMI (kg/m2) ↓ FM (g/cm2) ↓ Weight (kg) ↓ |
IGF-1 (ng/mL) ↑ IGFBP-3 (ng/mL) ↑ |
- |
| Glucagon-like peptide 1 receptor agonist | |||
| Sze et al. (2011) 23) | - | Fasting glucose (mmol/L) ↓ Fasting insulin (mIU/L) ↑ |
- |
| Oxytocin | |||
| Kuppens et al. (2016 b) 28) | BMI (kg/m2) ↓ Body fat (%) ↓ Weight (kg) ↑ |
- | - |
| Damen et al. (2021) 19) | BMI (kg/m2) ↑ LBM (kg) ↑ Body fat (%) ↑ Weight (kg) ↑ |
Fasting glucose ↑ Fasting insulin ↑ |
- |
| Einfeld et al. (2014) 27) | - | - | unchanged |
| Selective methionine aminopeptidase 2 inhibitor | |||
| McCandless et al. (2017) 21) | LBM (kg) ↓ FM (kg) ↓ Weight (kg) ↓ |
Adiponectin (mg/L) ↑ | - |
| Serotonin releasing agent | |||
| Selikowitz et al. (1990) 26) | Weight (kg) ↓ | - | - |
| Somatostatin receptor agonist | |||
| De Waele et al. (2008) 25) | BMI (kg/m2) ↑ FM (kg) ↑ Body fat (%) ↑ Weight (kg) ↑ Height (cm) ↑ |
Fasting glucose (mg/dL) ↑ | - |
| Unacylated ghrelin analog | |||
| Allas et al. (2018) 22) | FM (%) ↓ Weight (kg) ↓ |
Fasting glucose (mmol/L) ↓ Fasting insulin (pmol/L) ↑ |
↓ |
BMI: body mass index, FM: fat mass, IGF-1: Insulin-like growth factor 1, IGFBP-3: Insulin-like growth factor-binding protein 3, LBM: lean body mass, mIU: milli international unit, SDS: standard deviation score, U: unit, ↑ = increased, ↓ = decreased